InflaRx NV (InflaRx NV) Inventory-to-Revenue : 3,536.50 (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is InflaRx NV Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. InflaRx NV's Average Total Inventories for the quarter that ended in Dec. 2023 was $7.07 Mil. InflaRx NV's Revenue for the three months ended in Dec. 2023 was $0.00 Mil. InflaRx NV's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 3,536.50.

InflaRx NV's Inventory-to-Revenue for the quarter that ended in Dec. 2023 increased from Sep. 2023 (18.28) to Sep. 2023 (3,536.50)

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. InflaRx NV's Days Inventory for the three months ended in Dec. 2023 was 2,137.12.

Inventory Turnover measures how fast the company turns over its inventory within a year. InflaRx NV's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.04.

InflaRx NV Inventory-to-Revenue Historical Data

The historical data trend for InflaRx NV's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InflaRx NV Inventory-to-Revenue Chart

InflaRx NV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Inventory-to-Revenue

Get a 7-Day Free Trial

179.67

InflaRx NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Inventory-to-Revenue	Get a 7-Day Free Trial															-	-	-	18.28	3,536.50

Competitive Comparison of InflaRx NV's Inventory-to-Revenue

For the Biotechnology subindustry, InflaRx NV's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InflaRx NV's Inventory-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InflaRx NV's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where InflaRx NV's Inventory-to-Revenue falls into.

InflaRx NV Inventory-to-Revenue Calculation

InflaRx NV's Inventory-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

	Inventory-to-Revenue (A: Dec. 2023 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (A: Dec. 2022 )	+	Total Inventories (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )
=	( (0	+	12.397)	/	1 )	/	0.069
=	12.397					/	0.069
=	179.67

InflaRx NV's Inventory-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

	Inventory-to-Revenue (Q: Dec. 2023 )
=	Average Total Inventories					/	Revenue
=	( (Total Inventories (Q: Sep. 2023 )	+	Total Inventories (Q: Dec. 2023 ))	/	count )	/	Revenue (Q: Dec. 2023 )
=	( (1.749	+	12.397)	/	2 )	/	0.002
=	7.073					/	0.002
=	3,536.50

InflaRx NV (NAS:IFRX) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

InflaRx NV's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	7.073	/	0.302	*	365 / 4
	=	2,137.12

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

InflaRx NV's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	0.302	/	7.073
	=	0.04

InflaRx NV Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of InflaRx NV's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

InflaRx NV (InflaRx NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InflaRx NV (NAS:IFRX) » Definitions » Inventory-to-Revenue

Comparable Companies

Traded in Other Exchanges

IF0:Germany IF0:Germany

Address

Winzerlaer Strasse 2, Jena, DEU, 07745

Website

https://www.inflarx.de

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.